News

Successful combination: existing drugs boost cancer vaccine responsesInovio's universal avian flu vaccine generates protective antibody responses in phase 1Update on NewLink’s HyperAcute cancer immunotherapy productsGhana and Rwanda expand national immunization programsNews studies: Combining P...

Full description

Saved in:
Bibliographic Details
Main Author: Eva M. Riedmann
Format: Article
Language:English
Published: Taylor & Francis Group 2012-07-01
Series:Human Vaccines & Immunotherapeutics
Online Access:https://www.tandfonline.com/doi/10.4161/hv.21443
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850054501074993152
author Eva M. Riedmann
author_facet Eva M. Riedmann
author_sort Eva M. Riedmann
collection DOAJ
description Successful combination: existing drugs boost cancer vaccine responsesInovio's universal avian flu vaccine generates protective antibody responses in phase 1Update on NewLink’s HyperAcute cancer immunotherapy productsGhana and Rwanda expand national immunization programsNews studies: Combining PROSTVAC with conventional cancer therapyPromising phase 1 data for the first "Cross-Kingdom“ vaccine Oral TB vaccine shows promise in phase 2 trial
format Article
id doaj-art-2f8bdd95e8874c20a155e2719ecbb213
institution DOAJ
issn 2164-5515
2164-554X
language English
publishDate 2012-07-01
publisher Taylor & Francis Group
record_format Article
series Human Vaccines & Immunotherapeutics
spelling doaj-art-2f8bdd95e8874c20a155e2719ecbb2132025-08-20T02:52:13ZengTaylor & Francis GroupHuman Vaccines & Immunotherapeutics2164-55152164-554X2012-07-018784685010.4161/hv.21443NewsEva M. RiedmannSuccessful combination: existing drugs boost cancer vaccine responsesInovio's universal avian flu vaccine generates protective antibody responses in phase 1Update on NewLink’s HyperAcute cancer immunotherapy productsGhana and Rwanda expand national immunization programsNews studies: Combining PROSTVAC with conventional cancer therapyPromising phase 1 data for the first "Cross-Kingdom“ vaccine Oral TB vaccine shows promise in phase 2 trialhttps://www.tandfonline.com/doi/10.4161/hv.21443
spellingShingle Eva M. Riedmann
News
Human Vaccines & Immunotherapeutics
title News
title_full News
title_fullStr News
title_full_unstemmed News
title_short News
title_sort news
url https://www.tandfonline.com/doi/10.4161/hv.21443
work_keys_str_mv AT evamriedmann news